OVID THERAPEUTICS INC (OVID) Earnings History & Surprises

NASDAQ:OVIDUS6904691010

Current stock price

1.97 USD
-0.04 (-1.99%)
At close:
1.97 USD
0 (0%)
After Hours:

OVID Earnings overview

Past quarterly earnings results for OVID THERAPEUTICS INC (OVID), including EPS and revenue actuals, analyst estimates, and surprise percentages. This page focuses on historical performance (not forecasts).

Earnings Snapshot

Next Earnings Date

Upcoming
Release Date
Mar 16, 2026
Period
Q4 / 2025
EPS Estimate
-$0.12
Revenue Estimate
13.597K

Last Reported

Most Recent
Release Date
Nov 12, 2025
Period
Q3 / 2025
EPS Reported
-$0.17
EPS Surprise
-11.20%
Revenue Surprise
-1.54%

Beat Rate

Last 8 Quarters
69%
EPS and Revenue beats vs estimates

Quarterly Earnings Historical Results

EPS & Revenue History (in USD): Actual vs estimated values, surprises, q2q growth and acceleration numbers quarterly history.

QuarterEPSEPS EstEPS SurpriseEPS Q2QRevenueRevenue EstRevenue SurpriseRevenue Q2Q
Q3 2025 -0.17 -0.15 -11.20% 15.00% 132K 134.059K -1.54% -23.70%
Q2 2025 -0.06 -0.16 63.62% -150.00% 6.272M 78.203K 7,920.11% 3,611.24%
Q1 2025 -0.14 -0.14 -0.43% 17.65% 130K 51K 154.90% -12.16%
Q4 2024 -0.13 -0.17 23.22% 40.91% 76K 193.076K -60.64% -46.48%
Q3 2024 -0.20 -0.21 3.83% -25.00% 173K 88.883K 94.64% 58.76%
Q2 2024 0.12 -0.23 152.99% 166.67% 169K 71.4K 136.69% 125.33%
Q1 2024 -0.17 -0.22 23.51% 10.53% 148K 60.761K 143.58% 123.70%
Q4 2023 -0.22 -0.05 -333.89% -37.50% 142K 57.63K 146.40% -
Q3 2023 -0.16 -0.19 16.83% 5.88% 108.97K 51K 113.67% -
Q2 2023 -0.18 -0.21 13.75% 14.29% 75K 48.705K 53.99% -
Q1 2023 -0.19 -0.17 -8.77% 17.39% 66.16K 19.043K 247.42% -95.27%
Q4 2022 -0.16 -0.19 13.93% -60.00% - -
Q3 2022 -0.17 -0.22 22.21% - - -
Q2 2022 -0.21 -0.25 17.23% 8.70% - -
Q1 2022 -0.23 -0.21 -8.80% -109.09% 1.4M - -99.33%
Q4 2021 -0.10 -0.16 39.20% 70.59% - -100.00%
Q3 2021 -0.17 -0.19 9.30% 39.29% - -100.00%
Q2 2021 -0.23 -0.17 -39.19% 43.90% - -
Q1 2021 2.53 1.71 47.80% 783.78% 208.4M 123.05M 69.36% -
Q4 2020 -0.34 -0.32 -7.58% - 5.7M 4.248M 34.18% -
Q3 2020 -0.28 -0.37 24.14% - 6.9M 84.997K 8,017.97% -
Q2 2020 -0.41 -0.36 -12.77% - - -
Q1 2020 -0.37 -0.34 -9.38% - - -

Notes

  • EPS and Revenue values are non-GAAP when available, otherwise GAAP.
  • Surprise % is (Actual - Estimate) / |Estimate|. Green indicates positive surprise, red negative.
  • Q2Q % is quarter-over-quarter growth. Green indicates growth, red indicates decline.
  • Green right border indicates acceleration for sales or earnings growth. Acceleration is the case when the current Q2Q is above the previous Q2Q.

Earnings Q2Q Performance Trends

EPS Historical Q2Q growth and Acceleration

OVID EPS Q2Q GrowthOVID EPS Q2Q GrowthEPS Q2Q Growth Q1/21 Q3/21 Q1/22 Q3/22 Q1/23 Q3/23 Q1/24 Q3/24 Q1/25 Q3/25 Q1/26 Q3/26 0 200 400 600

Revenue Historical Q2Q growth and Acceleration

OVID Revenue Q2Q GrowthOVID Revenue Q2Q GrowthRevenue Q2Q Growth Q3/21 Q4/21 Q1/22 Q1/23 Q1/24 Q2/24 Q3/24 Q4/24 Q1/25 Q2/25 Q3/25 Q4/25 Q1/26 Q2/26 Q3/26 Q4/26 0 1K 2K 3K

Surprise distribution (Last 4 Quarters)

EPS beat statistics

EPS beat (4)
2
Average EPS beat (4)
18.80%
Max EPS beat (4)
63.62%
Min EPS beat (4)
-11.20%

Revenue beat statistics

Revenue beat (4)
2
Average Revenue beat (4)
2,003.21%
Max Revenue beat (4)
7,920.11%
Min Revenue beat (4)
-60.64%

Analysis

In the last 4 quarters, OVID has beaten EPS estimates in 2 out of 4 releases
OVID has beaten revenue estimates in 2 out of the last 4 releases
In the last 4 quarters, OVID has beaten the EPS estimates by 18.8% on average.
In the last 4 quarters, OVID has beaten the revenue estimates by 2003.2% on average.

OVID THERAPEUTICS INC / OVID Earnings FAQ

Can you provide the last earnings date for OVID THERAPEUTICS INC?

OVID THERAPEUTICS INC (OVID) last reported earnings on 11/12/2025.

Did OVID THERAPEUTICS INC (OVID) beat earnings estimates last quarter?

OVID THERAPEUTICS INC (OVID) missed EPS estimates and missed revenue estimates in the most recent quarter.

What percentage of the time does OVID stock beat earnings estimates?

In the last 4 quarters, OVID THERAPEUTICS INC (OVID) has beaten EPS estimates in 2 out of 4 releases.